FDF. I. Devlikamova

F. I. Devlikamova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


F. I. Devlikamova has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”

    by A.E. Barulin, M.A. Bakhtadze, O.S. Davydov, F.I. Devlikamova, D.A. Iskra, P.P. Kalinsky, A.E. Karateev, M.L. Kukushkin, O.V. Kurushina, T.I. Nasonova, et al.

    In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.

  • Clinical efficacy of eperisone in the treatment of patients with musculoskeletal pain

    by F.I. Devlikamova, S.A. Belov

    Objective. To study the clinical efficacy and safety of epirisone hydrochloride (Stezium) in the treatment of patients with skeletal muscle pain. Material and methods. One hundred forty-two 142 patients with non-specific musculoskeletal pain, mean age 46.2±17.8 years, have been enrolled in the study. The study was conducted according to the registered indication for Stezium — diseases of the musculoskeletal system accompanied by painful muscle spasms. Patients received Stezium 75 mg, extended-release, film-coated tablets, twice a day after meals for 14 days. All patients had undergone clinical examination before the prescription of the drug and on the 15th day using a visual analogue scale (VAS), a verbal analogue scale for pain assessing, a visual analogue scale (EQ-VAS) for the European Quality of Life Questionnaire (EQ-5D-3L), and patient assessment of the treatment effectiveness with Likert scale. Results. Quantitative indicators of pain assessment using analog scales statistically significant decreased (p<0.001) against the background of the treatment with Stezium, which indicates a significant analgesic effect of the therapy. Analysis of patient’s health condition showed an increase in the quality of life (from 60.22±10.45 to 74.11±11.53 points; p<0.001), which confirms the effectiveness of the performed therapy. The patient’s assessment of the overall treatment effect on the Likert scale demonstrated positive trend — 85.21% of patients noted significant clinical effect. Conclusion. The study results demonstrated the clinical efficacy and safety of extended-release film-coated tablets eperisone hydrochloride 75 mg for the treatment of musculoskeletal pain.

  • Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, O.V. Kurushina, D.I. Lebedeva, et al.

    Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.

  • Hereditary neuropathy with liability to pressure palsies: literature review and clinical case report

    by F. I. Devlikamova, D. R. Safina

    Hereditary neuropathy with a tendency to pressure palsies is a rare form of autosomal dominant hereditary peripheral neuropathy. This article reviews this disease literature. Typical changes based on family history, clinical presentation, stimulation electromyography, nerve ultrasound and genetic testing along with the disease progression and patient management strategies are presented. This article presents clinical case of hereditary neuropathy with a tendency to pressure palsies in a 21-year-old man with 9 months prospective follow-up. Nerve ultrasound, along with stimulation electromyography, has proven to be a key diagnostic method for hereditary neuropathy with a tendency to pressure palsies. The detection of two or more painless tunnel syndromes (including those detected by stimulation electromyography and ultrasound) in young patients may prompt testing for the PMP22 gene, and if detected, family genetic testing.

  • Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, V.V. Kim, O.V. Kurushina, et al.

    Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.

  • Efficacy and safety of ipidacrine (Neuromidin) in patients with diabetic polyneuropathy: results of an open-label comparative study

    by An.B. Danilov, I.V. Guryeva, Yu.V. Karakulova, O.V. Kurushina, A.E. Barulin, F.I. Devlikamova, V.A. Shirokov

    Objective. To assess the efficacy and safety of two ipidacrine (Neuromidin) treatment regimens-a stepwise regimen (intramuscular administration followed by oral therapy) and an oral-only regimen-in patients with type 1 or type 2 diabetes mellitus (DM) and confirmed diabetic polyneuropathy (DPN). Material and methods. In an open-label comparative study, the efficacy and safety of ipidacrine (Neuromidin) were evaluated in 90 patients with DPN receiving conventional antidiabetic therapy. Patients were assigned to three groups of 30 each: 1st — stepwise ipidacrine therapy (initial intramuscular administration followed by oral therapy); 2nd — oral ipidacrine therapy only; 3rd — control group (conventional antidiabetic therapy without ipidacrine). The treatment duration was 60 days. DPN was assessed using the Neuropathy Symptom Score (NSS), Neuropathy Disability Score (NDS), and Total Symptom Score (TSS). The intensity of neuropathic pain was evaluated using the Numeric Rating Scale (NRS). In addition, glycated hemoglobin (HbA1c), cognitive status (Mini-Mental State Examination, MMSE), and electroneuromyography of the peroneal nerve were assessed. Results. Both treatment groups demonstrated a significant improvement in DPN parameters (p<0.001). The stepwise regimen resulted in a more pronounced improvement in NSS (p=0.048). The intensity of neuropathic pain on the NRS significantly decreased in both treatment groups (p<0.001). A significant improvement in glycemic control parameters was observed in the active treatment groups. A mild but statistically significant improvement in cognitive function as assessed by MMSE was also noted (p≤0.04). Electroneuromyography showed positive dynamics in sensory fiber parameters. The safety profile was favorable in both treatment groups. Conclusion. Both ipidacrine regimens demonstrated high efficacy as part of combination therapy for DPN. The stepwise regimen likely provided a faster onset of clinical effect. The safety profile was favorable, and no serious adverse events were observed.


  • Musculoskeletal back pain, issues of optimizing diagnosis and treatment

    by V. A. Parfenov, L. I. Alekseeva, N. V. Vakhnina, F. I. Devlikamova, E. V. Moroz, N. V. Titova, M. M. Tanashyan

    Nonspecific (musculoskeletal) neck and back pain (NNBP) is one of the most common reasons for seeking medical advice. The diagnosis of NNBP is based on clinical examination, the absence of signs of dangerous disease ('red flags'), radiculopathy and spinal stenosis. If there are no signs of a dangerous disease, early (within the first 4 weeks) instrumental examination, including magnetic resonance imaging, is not recommended. Fibromyalgia is common among patients with chronic NNBP, but it is rarely diagnosed due to poor awareness among doctors about its manifestations and diagnostic criteria. In NNBP, it is recommended to inform the patient about the favourable prognosis of the disease and risk factors, the need to avoid excessive static and physical exertion, incorrect positions and postures, and the advisability of maintaining physical, social and professional activity. Nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants are most commonly used to relieve NNBP. Extensive clinical experience has been accumulated regarding the efficacy and safety of aceclofenac (Airtal) as an NSAID and tolperisone (Mydocalm) as a muscle relaxant in the treatment of NNBP. The combination of aceclofenac (Airtal) and tolperisone (Mydocalm) is more effective than monotherapy, as it reduces the duration of NSAID use and lowers the risk of complications from long-term use. For subacute and chronic NNBP, a multimodal approach is most effective, which should include physical exercise (therapeutic physical training – TPT), manual therapy, and, for some patients, psychological therapy methods as non-drug methods. In cases where chronic back pain is caused by fibromyalgia, antiepileptic drugs may be effective as part of complex therapy, among which gabapentin (Tebantin) has been shown to be effective and safe. To prevent NNBP, therapeutic exercise, an educational programme on avoiding excessive static and physical stress, and incorrect positions and postures are recommended.


  • Cocarnit in complex therapy of diabetic peripheral polyneuropathy

    by F.I. Devlikamova, D.R. Safina

    Objective. Study of the effectiveness of Cocarnit drug in diabetic peripheral polyneuropathy (DPPN) combination therapy. Material and methods. The study involved 40 patients with DPPN aged 38 to 74 years (mean age 62.33±1.27 years), with type 2 diabetes mellitus 2—36 years duration (mean 12.38±1.25 years); 4 months to 28 years (mean 6.27±1.06 years) had passed since the first symptoms of polyneuropathy. They received Cocarnit 2 ml per day for 18 days and gabapentin with individual dose selection. Results. The treatment shows significant decrease of pain intensity in patients with positive dynamics from «severe» at the beginning of the study to «weak» by the end of the study. Significant positive dynamics of the severity of neuropathy symptoms during the combined therapy were shown by DN4 questionnaire and the NSS scale, assessment of complaints and physical examination results using the MNSI diagnostic questionnaire, and the general clinical impression on the CGI-C scale. A positive tendency in the s-ENMG results was revealed with more significant improvement changes in the axoplasmic amperage along the peroneal nerve, superficial peroneal nerve and the feet VCSP. The results of the quality of life assessment objectively confirm the improvement in the patients’ condition as a result of the therapy. The doses of gabapentin during Cocarnit treatment were low and did not reach the usual therapeutic doses, against the background of a statistically significant decrease in pain syndrome. Conclusion. Cocarnit is an effective drug for patients with DPPN treatment. The combined use of Cocarnit with gabapentin allows to reduce the dose of gabapentin and the risk of its side effects helping to restore peripheral nerves in DPPN.


  • Open Access

    “I’m dizzy”: How to help a patient with dizziness effectively and quickly

    by D. Kh. Khaibullina, Yu. N. Maksimov, F. I. Devlikamova, Д. Х. Хайбуллина

    One of the most common reasons for seeking medical help from doctors of various specialties is a disturbance of balance function, described by patients as dizziness. Despite the apparent simplicity and unambiguity of the complaint, it turns out that under this term patients mean completely different conditions: instability, unsteadiness when walking, swaying, nausea, pre-fainting condition, “fog in the head”, impaired coordination, etc. Often, the patient not only finds it difficult to independently describe his feelings, but also simultaneously lists several descriptors. It is not always possible to specify the patient’s desires, which complicates the diagnosis of dizziness and the establishment of the etiological factor. In connection with the above, an algorithm is currently used in the diagnosis of dizziness, which includes an assessment of the vestibular syndrome by the nature of the course (acute, episodic, chronic), identification of provoking factors (triggers), concomitant symptoms, supplemented by a physical examination, and, if necessary, paraclinical methods. In the treatment of dizziness, priority is given to its rapid and effective relief. For this purpose, drugs are used – vestibular suppressants. Given the high prevalence of comorbid conditions requiring the simultaneous use of several drugs, combination drugs have an advantage. A combination of cinnarizine and dimenhydrinate has demonstrated high efficiency and safety as a symptomatic therapy for dizziness of various origins. The combination of drug therapy with vestibular rehabilitation methods allows achieving better results and longer remission even in chronic cases of dizziness.


  • Open Access

    The main types of parasomnias in children and methods of their correction

    by Станислав Андреевич Белов, Булат Эдуардович Губеев, Оксана Александровна Алексеева, Фарида Ильдусовна Девликамова

    The purpose of the article is to present an up-to-date review of parasomnia in childhood and ways of their pharmacological correction. Unintended motor phenomena in children are classified into three main groups: arousal disorders, parasomnia associated with REM sleep, and other types of parasomnia, but scientific approaches consider this problem in a more multifaceted way, and modified triggers should be studied. The types of pathogenesis of REM and slow-wave sleep, and types of parasomnia in these phases are described in detail. When making a diagnosis, it is necessary to take into account the medical history and identification of triggers, and in this the objective role of video polysomnography is assigned. Attention should be paid to the pharmacological correction of parasomnia, in which drugs of various groups (antidepressants, tranquilizers, anxiolytics, adaptogens) are prescribed. However, it is extremely important for doctors who face this problem to understand their nature and be able to make a differential diagnosis.